Skip to main content
SpringerLink
Log in

Clinical Applications of Proteomics

  • Chapter
Cancer Chemoprevention

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 852 Accesses

Abstract

The field of molecular medicine is moving beyond genomics to proteomics, which is often viewed as creation of a compendium “master list” of all proteins and their possible post-translational modifications. However, the effort made to elucidate this index is not likely to be rewarded by any real clinical impact, as the function of proteins is closely tied to their cellular, tissue, and physiological context. The ultimate goal of clinical proteomics (the translational subdiscipline of the larger field) is really twofold. First, characterize information flow through protein networks—which are deranged as a cause or consequence of disease processes as they exist, not in cell culture or animal models systems, but in the tissue microenvironment of the host—and how that information content changes during therapeutic intervention; second, develop biomarker profiling technologies to detect disease earlier and treat it more effectively.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000;1:48–56.

    Article  PubMed  CAS  Google Scholar 

  2. Ideker T, Thorsson V, Ranish JA, et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001;292:929–934.

    Article  PubMed  CAS  Google Scholar 

  3. Schwikowski B, Uetz P, Fields S. A network of protein-protein interactions in yeast. Nat Biotechnol 2000;18:1257–1261.

    Article  PubMed  CAS  Google Scholar 

  4. Legrain P, Jestin JL, Schachter V. From the analysis of protein complexes to proteome-wide linkage maps. Curr Opin Biotechnol 2000;4:402–407.

    Article  Google Scholar 

  5. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001;411:355–365.

    Article  PubMed  CAS  Google Scholar 

  6. Pawson T. Protein modules and signaling networks. Nature 1995;373:573–580.

    Article  PubMed  CAS  Google Scholar 

  7. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In Principles and Practice of Gynecologic Oncology. Hoskins WJ, Perez CA, Young RC, eds. Lippincott Williams & Wilkins, Philadelphia, 2000: pp. 981–1058.

    Google Scholar 

  8. Menon V, Jacobs IJ. Tumor markers. In Principles and Practice of Gynecologic Oncology. Hoskins WJ, Perez CA, Young RC, eds. Lippincott Williams & Wilkins, Philadelphia, 2000; pp. 165–182.

    Google Scholar 

  9. Bast RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883–887.

    PubMed  Google Scholar 

  10. Menon U, Jacobs IJ. Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 2000;12:39–42.

    Article  PubMed  CAS  Google Scholar 

  11. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 1999;353:1207–1210.

    Article  PubMed  CAS  Google Scholar 

  12. Cohen LS, Escobar PF, Scharm C, et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001;82:40–48.

    Article  PubMed  CAS  Google Scholar 

  13. Richter R, Schulz-Knappe P, Schrader M, et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromotogr B Biomed Sci Appl 1999;726:25–35.

    Article  CAS  Google Scholar 

  14. Adam BL, Vlahou A, Semmes OJ, Wright GL Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001;1:1264–1270.

    Article  PubMed  CAS  Google Scholar 

  15. Carter D, Douglass JF, Cornellison CD, et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 2002;41:6714–6722.

    Article  PubMed  CAS  Google Scholar 

  16. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002;62:1868–1875.

    PubMed  CAS  Google Scholar 

  17. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029–6033.

    PubMed  CAS  Google Scholar 

  18. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–577.

    Article  PubMed  CAS  Google Scholar 

  19. Petricoin EF 3rd, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576–1578.

    PubMed  CAS  Google Scholar 

  20. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–1304.

    PubMed  CAS  Google Scholar 

  21. Adam B-L, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609–3614.

    PubMed  CAS  Google Scholar 

  22. Ball G, Mian S, Holding F, et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 2002;18:395–404.

    Article  PubMed  CAS  Google Scholar 

  23. Ting KL, Lee RC, Chang CL, Guarino AM. The relationship between the mass spectra of drugs and their biological activity—an application of artificial intelligence to chemistry. Comput Biol Med 1975;4:301–332.

    Article  PubMed  CAS  Google Scholar 

  24. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Disc 2002;1:153–161.

    Article  CAS  Google Scholar 

  25. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.

    Article  PubMed  CAS  Google Scholar 

  26. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531–537.

    Article  PubMed  CAS  Google Scholar 

  27. Lindahl D, Palmer J, Edenbrandt L. Myocardial SPET: artificial neural networks describe extent and severity of perfusion defects. Clin Physiol 1999;19:497–503.

    Article  PubMed  CAS  Google Scholar 

  28. Lapuerta P, L’Italien GJ, Paul S, et al. Neural network assessment of perioperative cardiac risk in vascular surgery patients. Med Decis Making 1998;18:70–75.

    Article  PubMed  CAS  Google Scholar 

  29. Holland JH, ed. Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence, 3rd ed. MIT Press, Cambridge, MA, 1994.

    Google Scholar 

  30. Kohonen T. The self-organizing map. Proc IEEE 1990;78: 1464–1480.

    Article  Google Scholar 

  31. Kohonen. T. Self-organizing formation of topologically correct feature maps. Biol Cybern 1982;43:59–69.

    Article  Google Scholar 

  32. Tou JT, Gonzalez R. Pattern classification by distance functions. In Pattern Recognition Principles. Tou JT, Gonzalez R, eds. Addison Wesley, Reading, MA, 1974, pp. 75–109.

    Google Scholar 

  33. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274:998–1001.

    Article  PubMed  CAS  Google Scholar 

  34. Emmert-Buck MR, Gillespie JW, Paweletz CP, et al. An approach to proteomic analysis of human tumors. Mol Carcinog 2000;27:158–165.

    Article  PubMed  CAS  Google Scholar 

  35. Craven RA, Totty N, Harnden P, et al. Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol 2002;160:815–822.

    PubMed  CAS  Google Scholar 

  36. Ornstein DK, Gillespie JW, Paweletz CP, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000;21: 2235–2242.

    Article  PubMed  CAS  Google Scholar 

  37. Wulfkuhle JD, McLean KC, Paweletz CP, et al. New approaches to proteomic analysis of breast cancer. Proteomics 2001;1:1205–1215.

    Article  PubMed  CAS  Google Scholar 

  38. Jones MB, Krutzsch H, Shu H, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002;2:76–84.

    Article  PubMed  CAS  Google Scholar 

  39. Knezevic V, Leethanakul C, Bichsel VE, et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 2001;1:1271–1278.

    Article  PubMed  CAS  Google Scholar 

  40. Ahram M, Best CJ, Flaig MJ, et al. Proteomic analysis of human prostate cancer. Mol Carcinog 2002;33:9–15.

    Article  PubMed  CAS  Google Scholar 

  41. Paweletz CP, Gillispie JW, Ornstein DK, et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res 2000;49: 34–42.

    Article  CAS  Google Scholar 

  42. Cazares LH, Adam BL, Ward MD, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002;8:2541–2552.

    PubMed  CAS  Google Scholar 

  43. Shen Y, Tolic N, Zhao R, et al. High-throughput proteomics using high-efficiency multiple-capillary liquid chromatography with on-line high-performance ESI FTICR mass spectrometry. Anal Chem 2001;73:3011–3021.

    Article  PubMed  CAS  Google Scholar 

  44. Li J, Wang C, Kelly JF, et al. Rapid and sensitive separation of trace level protein digests using microfabricated devices coupled to a quadrupole—time-of-flight mass spectrometer. Electrophoresis 2000;21:198–210.

    Article  PubMed  CAS  Google Scholar 

  45. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope coded affinity tags. Nat Biotechnol 1999,17:994–999.

    Article  PubMed  CAS  Google Scholar 

  46. Washburn MP, Wolters D, Yates JR. Large scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001,19:242–247.

    Article  PubMed  CAS  Google Scholar 

  47. Krutchinsky AN, Kalkum M, Chait BT. Automatic identification of proteins with a MALDI-quadrupole ion trap mass spectrometer. Anal Chem 2001;73:5066–5077.

    Article  PubMed  CAS  Google Scholar 

  48. Washburn MP, Ulaszek R, Deciu C, et al. Analysis of quantitative proteomic data generated via multidimensional protein identification technology. Anal Chem 2002;74:1650–1657.

    Article  PubMed  CAS  Google Scholar 

  49. Zhou H, Ranish JA, Watts JD, Aebersold R. Quantitative proteome analysis by solid-phase isotope tagging and mass spectrometry. Nat Biotechnol 2002;20:512–515.

    Article  PubMed  CAS  Google Scholar 

  50. Zhou G, Li H, DeCamp D, et al. 2D differential in-gel electrophoresis for the identification of human esophageal squamous cell cancer specific protein markers. Mol Cell Proteomics 2002;1:117–124.

    Article  PubMed  CAS  Google Scholar 

  51. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000;289:1760–1763.

    PubMed  CAS  Google Scholar 

  52. Kuruvilla FG, Shamji AF, Sternson SM, et al. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 2002;416:653–657.

    Article  PubMed  CAS  Google Scholar 

  53. Walter G, Bussow K, Lueking A, Glokler J. High-throughput protein arrays: prospects for molecular diagnostics. Trends Mol Med 2002;8:250–253.

    Article  PubMed  CAS  Google Scholar 

  54. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20:1981–1989.

    Article  PubMed  CAS  Google Scholar 

  55. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249–2256.

    PubMed  CAS  Google Scholar 

  56. Knezevic V, Leethanakul C, Bichsel VE, et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 2001;1:1271–1278.

    Article  PubMed  CAS  Google Scholar 

  57. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 2001;286:2211–2214.

    Article  PubMed  CAS  Google Scholar 

  58. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000;1:48–56.

    Article  PubMed  CAS  Google Scholar 

  59. Karpati G, Li H, Nalbantoglu J. Molecular therapy for glioblastoma. Curr Opin Mol Ther 1999;1:545–552.

    PubMed  CAS  Google Scholar 

  60. Brown CK, Kirkwood JM. Targeted therapy for malignant melanoma. Curr Oncol Rep 2001 Jul;3(4):344–352.

    Article  PubMed  CAS  Google Scholar 

  61. Frankel AE, Sievers EL, Scheinberg DA. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother Radiopharm 2000;15:459–476.

    Article  PubMed  CAS  Google Scholar 

  62. Cheng JD, Rieger PT, von Mehren M, et al. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs 2000;16:2–12.

    Article  PubMed  CAS  Google Scholar 

  63. Gasparini G, Gion M. Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints. Cancer J Sci Am 2000;6:117–131.

    CAS  Google Scholar 

  64. Cimoli G, Bagnasco L, Pescarolo MP, et al. Signaling proteins as innovative targets for antineoplastic therapy: our experience with the signaling protein c-myc. Tumori 2001;87:S20–S23.

    PubMed  CAS  Google Scholar 

  65. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.

    Article  PubMed  Google Scholar 

  66. Normanno N, Campiglio M, De LA, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65–72.

    Article  PubMed  CAS  Google Scholar 

  67. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;16:7184–7188.

    Google Scholar 

  68. Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001;61: 4892–4900.

    PubMed  CAS  Google Scholar 

  69. Vile RG, Chong H. Immunotherapy III: combinatorial molecular immunotherapy—a synthesis and suggestions. Cancer Metastasis Rev 1996;15:351–364.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. FDA-NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Washington, DC

    Emanuel F. Petricoin III PhD

  2. FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Lance A. Liotta MD, PhD

Authors
  1. Emanuel F. Petricoin III PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lance A. Liotta MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biomedical Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Gary J. Kelloff MD

  2. Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Ernest T. Hawk MD, MPH

  3. CCS Associates, Mountain View, CA

    Caroline C. Sigman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Petricoin , E.F., Liotta, L.A. (2005). Clinical Applications of Proteomics. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-768-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-768-0_9

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-077-9

  • Online ISBN: 978-1-59259-768-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation